AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Today's Research Daily features a real-time scorecard of the ongoing Q4 earnings season, in addition to the usual updated analyst reports on 16 major stocks, including Walmart Inc. (WMT), Visa Inc. (V ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Allergan Aesthetics, an AbbVie company , announced a nationwide open casting call in search of the next Faces of Natrelle®, encouraging women who have ...

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

TrialWire, a leader in clinical trial recruitment innovation, launched its groundbreaking AI Voice Screen service as part of the TrialWire Recruitment Platform powered by Salesforce Health Cloud, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...